TIANDA PHARMA (0455.HK)
- Previous Close
0.140 - Open
0.156 - Bid 0.143 x --
- Ask 0.156 x --
- Day's Range
0.150 - 0.156 - 52 Week Range
0.131 - 0.275 - Volume
102,000 - Avg. Volume
36,338 - Market Cap (intraday)
322.506M - Beta (5Y Monthly) -0.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.030 - Earnings Date Mar 28, 2025
- Forward Dividend & Yield 0.00 (1.73%)
- Ex-Dividend Date Jun 13, 2024
- 1y Target Est
--
Tianda Pharmaceuticals Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of pharmaceutical, biotechnology, and healthcare products in Mainland China, Hong Kong, and Australia. It operates through the Chinese Medicine, Pharmaceuticals and Medical Technologies, and Medical and Healthcare Services segments. The company offers Chinese herbal medicine, Chinese medicine decoction pieces, Chinese medicine products, and Chinese medicine clinical services. It also produces pharmaceutical products focusing on cardiovascular and cerebrovascular chronic diseases, respiratory infections, and pediatric diseases. In addition, the company trades agricultural by-products. The company was formerly known as Tianda Holdings Limited and changed its name to Tianda Pharmaceuticals Limited in September 2012. The company was incorporated in 1992 and is headquartered in Central, Hong Kong. Tianda Pharmaceuticals Limited is a subsidiary of Tianda Group Limited.
www.tiandapharma.com701
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 0455.HK
View MorePerformance Overview: 0455.HK
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0455.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0455.HK
View MoreValuation Measures
Market Cap
322.51M
Enterprise Value
364.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.98
Price/Book (mrq)
0.64
Enterprise Value/Revenue
1.10
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.60%
Return on Assets (ttm)
-4.02%
Return on Equity (ttm)
-11.19%
Revenue (ttm)
329.94M
Net Income Avi to Common (ttm)
-61.37M
Diluted EPS (ttm)
-0.030
Balance Sheet and Cash Flow
Total Cash (mrq)
91.83M
Total Debt/Equity (mrq)
25.20%
Levered Free Cash Flow (ttm)
-71.25M